GlassScriptPhysician profile
Trent D Douglas
NPI 1023176302
$12,054.51
in general payments reported to CMS, 2019-2025
18 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,068 · 2020: $1,120 · 2021: $1,079 · 2022: $1,759 · 2023: $1,696 · 2024: $1,369 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314 · Travel and Lodging: $822 · Consulting Fee: $480 · Long Term Medical Supply Or Device Loan: $326 · Gift: $87.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.93 |
| Travel and Lodging | $821.66 |
| Consulting Fee | $480.00 |
| Long Term Medical Supply Or Device Loan | $326.00 |
| Gift | $87.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $3,600.60 | 2019-2023 | Iovera |
| Heron Therapeutics, INC. | $3,325.06 | 2019-2020 | |
| Abbvie INC. | $1,058.47 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Motiva USA, LLC | $727.27 | 2024-2025 | |
| Allergan, INC. | $639.36 | 2019-2022 | |
| Davol INC. | $614.59 | 2022-2025 | Phasix Mesh |
| Musculoskeletal Transplant Foundation INC. | $593.26 | 2024-2025 | |
| Integra Lifesciences Corporation | $326.00 | 2023 | Durasorb Monofilament Mesh |
| Bard Peripheral Vascular, INC. | $275.60 | 2021 | |
| Mentor Worldwide LLC | $191.84 | 2019-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $159.35 | 2019-2025 | Dysport |
| Axogen | $144.87 | 2019 | |
| Revance Therapeutics, INC. | $133.46 | 2024 | Daxxify |
| W. L. Gore & Associates, INC. | $125.00 | 2019 | |
| Tepha INC | $54.53 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $39.46 | 2024 | Ovitex 2s |
| Sientra, INC. | $29.95 | 2019 | |
| Merz North America, INC. | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trent Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.